TCBP

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.01
Percentage change 0.49	%

Peers: MRK PFE GILD JNJ AMGN REGN BMY VRTX IONS BIIB

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	0.03M	Perf Week	0.49%
Market Cap	0.05M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-29.33%
Income	-	PEG	-	EPS next Q	-	Inst Own	11.12%	Short Float	-	Perf Quarter	-81.43%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	42.96%	Short Ratio	0.17	Perf Half Y	-98.23%
Book/sh	1.99	P/B	0.87	EPS next Y	-	ROA	-	Short Interest	0.05M	Perf Year	-99.36%
Cash/sh	42.33	P/C	0.04	EPS next 5Y	-	ROE	-	52W Range	1.43 - 523.20	Perf YTD	-83.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	45.82%	ROI	-	52W High	-99.67%	Beta	-0.06
Dividend TTM	-	Quick Ratio	0.79	Sales past 5Y	-15.17%	Gross Margin	-	52W Low	21.49%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	0.79	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	29.32	Volatility	13.22% 18.10%
Employees	41	Debt/Eq	0.83	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	47.79
Option/Short	No / Yes	LT Debt/Eq	0.67	EPS Q/Q	-	Payout	-	Rel Volume	0.19	Prev Close	1.73
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	283.04K	Price	1.74
SMA20	-14.48%	SMA50	-62.95%	SMA200	-97.15%	Trades		Volume	17,823	Change	0.49%

Mar-05-25 08:30AM	TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company (PR Newswire) -10.82%
Feb-20-25 08:00AM	TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum (PR Newswire)
Feb-13-25 08:30AM	TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial (PR Newswire) -28.07%
Feb-10-25 10:00AM	TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial (PR Newswire) -5.71%
Feb-05-25 12:00PM	TCBP to Implement ADS Ratio Change (PR Newswire) -30.14%
08:30AM	Loading…
Jan-15-25 08:30AM	TCBP Announces H5N1 Proof of Concept Studies Intention (PR Newswire) -12.72%
Jan-13-25 08:45AM	TCBP to Present at Sequire Investor Summit 2025 (PR Newswire) +13.11%
Jan-06-25 09:26PM	TCBP Issues 25% Stock Dividend (PR Newswire)
09:26PM	/C O R R E C T I O N -- TC BioPharm/ (PR Newswire)
01:30PM	TCBP Trading Continues Unabated on Nasdaq Stock Exchange (PR Newswire)
Dec-31-24 10:15AM	TCBP Provides Update on Acquisition Strategy and Current Targets (PR Newswire) +6.09%
Dec-30-24 10:30AM	TCBP Issues 25% Stock Dividend (PR Newswire) -14.37%
Dec-20-24 08:30AM	TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients (PR Newswire)
Dec-18-24 08:30AM	TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend (PR Newswire) +38.59%
Dec-11-24 07:00AM	TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy (PR Newswire)
08:30AM	Loading…
Dec-04-24 08:30AM	TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial (PR Newswire) +5.83%
Nov-12-24 09:30AM	TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex Grant (PR Newswire)
Oct-30-24 08:30AM	TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements (PR Newswire) -17.90%
Oct-25-24 09:45AM	TCBP Responds to False Social Media Claim (PR Newswire) -19.19%
Oct-22-24 08:30AM	TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic (PR Newswire) +14.54%
Oct-03-24 08:30AM	TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening (PR Newswire) +11.66%
Sep-25-24 08:30AM	TCBP Announces Site Opening of Guys and St. Thomas Hospital (PR Newswire)
Sep-24-24 08:45AM	TCBP to Present at the 2024 ThinkEquity Conference in NYC (PR Newswire)
Sep-20-24 04:00PM	TCBP Announces First Patient Completed the Full Dose Regimen in ACHIEVE Clinical Trial (PR Newswire)
04:00PM	/C O R R E C T I O N -- TC BioPharm/ (PR Newswire)
Sep-12-24 08:30AM	TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial (PR Newswire) +15.60%
Sep-09-24 08:30AM	TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox (PR Newswire) -28.03%
Sep-06-24 04:00PM	TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox (PR Newswire)
Sep-05-24 08:30AM	TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Sep-03-24 08:30AM	TCBP Announces Dosing of 5 New Patients in ACHIEVE (PR Newswire) +30.70%
05:15PM	Loading…
Aug-28-24 05:15PM	TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering (PR Newswire) +17.14% +30.24%
01:50PM	TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications (PR Newswire)
Aug-15-24 01:00PM	TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b) (PR Newswire) +9.31%
11:30AM	TC BioPharm Announces Closing of $2.0 Million Public Offering (PR Newswire)
Aug-13-24 04:30PM	TC BioPharm Announces Pricing of $2.0 Registered Direct Offering (PR Newswire) -7.83% -8.77%
Jul-31-24 08:00AM	TCBP Announces Plan to Implement ADS Ratio Change (PR Newswire) -32.38%
Jul-22-24 08:00AM	TCBP Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia (PR Newswire) -5.12%
Jul-09-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-15-24 08:30AM	TCBP Announces Launch of Compassionate Use Program for TCB008 (PR Newswire)
May-06-24 01:01PM	TC BioPharm Announces Exercise of Warrants for 3.1 Million Gross Proceeds (PR Newswire)
11:32AM	ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range? (InvestorPlace)
11:07AM	Warren Buffett Just Gave Up on Paramount (PARA) Stock (InvestorPlace)
10:37AM	Why Is TC Biopharm (TCBP) Stock Up 51% Today? (InvestorPlace)
08:30AM	TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies (PR Newswire)
Apr-04-24 10:37AM	Why Is TC Biopharm (TCBP) Stock Up 78% Today? (InvestorPlace) +50.00%
08:32AM	TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies (PR Newswire)
Apr-02-24 08:30AM	TCBP Increasing Treatment Capacity with Expanded Manufacturing Process (PR Newswire)
Mar-19-24 08:30AM	TCBP Adjourns General Meeting Until a Later Date (PR Newswire) -9.88%
Mar-18-24 08:30AM	TCBP Announces Exercise of Series D Warrants For Cash (PR Newswire)
Mar-01-24 08:30AM	Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated 'The Big Biz Show' (PR Newswire) +5.56%
Feb-27-24 05:15PM	/C O R R E C T I O N -- TC BioPharm/ (PR Newswire) +5.91%
Feb-22-24 09:32AM	TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial (PR Newswire) +11.94%
Feb-15-24 08:30AM	TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe (PR Newswire)
Feb-14-24 08:30AM	TCBP Provides Shareholder Update and Highlights Upcoming Milestones (PR Newswire) -14.05%
Jan-29-24 08:30AM	TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show' (PR Newswire) -13.38%
Jan-18-24 08:30AM	TC BioPharm to Present at the Sequire Investor Summit (PR Newswire)
Jan-04-24 08:30AM	TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Jan-03-24 08:30AM	TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies (PR Newswire) -26.20%
Dec-22-23 08:30AM	TC BioPharm Announces Closing of $3.5 Million Public Offering (PR Newswire)
Dec-19-23 08:00AM	TC BioPharm Announces Pricing of $3.5 Million Public Offering (PR Newswire) -12.87%
Dec-18-23 11:15AM	TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D (PR Newswire)
Dec-13-23 06:30AM	TC BioPharm Announces Plan to Implement ADS Ratio Change (PR Newswire)
Nov-28-23 11:05AM	TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug (Zacks) -7.62%
Nov-27-23 08:45AM	TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia (PR Newswire) -25.52%
Nov-14-23 10:00AM	TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results (PR Newswire) +11.71%
Nov-02-23 01:30PM	TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials (PR Newswire)
Oct-25-23 08:00AM	TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements (PR Newswire)
Oct-24-23 08:45AM	Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments (PR Newswire) -6.88%
Oct-23-23 08:00AM	TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AML (PR Newswire) +9.94%
Sep-27-23 08:00AM	TC BioPharm to Present at the LD Micro Main Event XVI (PR Newswire)
Sep-05-23 08:30AM	TC BioPharm Announces Grant Funding in Collaboration with Queen Mary University of London (QMUL) (PR Newswire)
Aug-29-23 08:30AM	TC BioPharm to Present at H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Jul-31-23 08:30AM	TC BioPharm Maintains Nasdaq Listing (PR Newswire) +12.81%
Jul-06-23 09:08AM	TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast (Newsfile) -6.42%
May-24-23 09:00AM	TC BioPharm to Present at LD Micro Invitational XIII Conference on June 7, 2023 (PR Newswire)
May-04-23 06:29AM	TC Biopharm (Holdings) Full Year 2022 Earnings: Beats Expectations (Simply Wall St.) -8.11%
Apr-26-23 08:30AM	TC BioPharm Increases Allogeneic Car and Partnering Focus for Advancement of TCB-008 (PR Newswire) -10.14%
Apr-19-23 08:00AM	TC BioPharm to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Mar-30-23 04:15PM	TC BioPharm Announces Closing of $5.5 Million Public Offering (PR Newswire)
Mar-28-23 08:05AM	TC BioPharm Announces Pricing of $5.5 Million Public Offering (PR Newswire) -11.68%
Mar-22-23 08:30AM	TC Biopharm Announces Corporate Restructuring, Reduction in Overhead (PR Newswire)
Mar-16-23 12:00PM	TC BioPharm Receives Extension from Nasdaq Hearings Panel to Regain Compliance With Listing Rule 5550(b)(2) (PR Newswire) +8.40%
Mar-07-23 08:30AM	TC BioPharm Shifts Focus to FDA Clinical Trials (PR Newswire) -9.74%
Feb-23-23 08:30AM	TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer (PR Newswire) -11.13%
Feb-21-23 08:30AM	TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T cell Therapies (PR Newswire) -32.62%
Feb-14-23 08:30AM	TC BioPharm Announces New Chair of the Board, Arlene Morris (PR Newswire) +14.93%
Feb-13-23 04:15PM	TC BioPharm to Reschedule Shareholder Update Call and Webcast (PR Newswire) +6.68%
Feb-07-23 08:30AM	TC BioPharm Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort (PR Newswire)
Jan-30-23 08:30AM	TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division (PR Newswire)
Jan-20-23 08:30AM	TC BioPharm to Host Shareholder Update Call (PR Newswire) -11.73%
Jan-19-23 08:30AM	TC BioPharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1) (PR Newswire) -17.46%
Jan-17-23 08:30AM	TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology (PR Newswire) +10.04%
Jan-12-23 06:50AM	Daily Vickers Top Buyers & Sellers for 01/12/2023 (Argus Research) +11.50%
Dec-12-22 09:00AM	TC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder Update (PR Newswire)
Nov-30-22 06:43PM	TC BioPharm Announces Closing of $7.35 Million Private Placement (PR Newswire)
Nov-28-22 08:00AM	TC BioPharm Announces $7.35 Million Private Placement (PR Newswire) -31.91%
Nov-22-22 08:00AM	TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid Leukemia (PR Newswire)
Nov-21-22 05:55AM	TC Biopharm (Holdings) Plc's (NASDAQ:TCBP) biggest owners are individual investors who got richer after stock soared 11% last week (Simply Wall St.) -18.63%
Oct-26-22 08:30AM	TC BioPharm Announces Key Additions to Scientific Advisory Board, Expanding Cell Therapy Expertise (PR Newswire)
Oct-03-22 08:30AM	TC BioPharm to Present at Upcoming Investor Conferences (PR Newswire)

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TC BioPharm (Holdings) plc ADR

Upgrade your FINVIZ experience